Search - tctmd.com

Displaying 341 - 360 of 1879

Sort: Relevancy | Date

Presentation TCT 2021

Finding the Sweet Spot: Balancing Reducing Ischemic Risk and Reducing Bleeding Risk with Antiplatelet Therapy

Presenter: Deepak Bhatt

November 05, 2021

Presentation TCT 2021

When to Shorten DAPT: Key Messages

Presenter: George Dangas

November 05, 2021

Presentation TCT 2021

Antiplatelet Therapy for Patients with Diabetes Undergoing PCI

Presenter: Deepak Bhatt

November 05, 2021

Presentation TCT 2021

Introduction

Presenter: George Dangas

November 05, 2021

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

Todd Neale

November 05, 2021

Presentation TCT 2021

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

Presenter: Pieter Smits

November 05, 2021

News Conference News TCT 2021

OCT Guidance Cuts Stent Use in STEMI Without Plaque Rupture: EROSION III

Shelley Wood

November 04, 2021

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

News Conference News TCT 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

L.A. McKeown

November 04, 2021

News Conference News TCT 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Yael L. Maxwell

October 22, 2021

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Shelley Wood

October 15, 2021

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

Todd Neale

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

Todd Neale

October 13, 2021

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Shelley Wood

October 08, 2021

News Daily News

Women Stand to Gain the Most From Standardized STEMI Protocols

Michael O'Riordan

September 30, 2021

News Daily News

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

Michael O'Riordan

September 20, 2021

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Caitlin E. Cox

September 15, 2021

News Daily News

Long-term Anticoagulation After Unprovoked VTE: New Insights

Shelley Wood

September 13, 2021

Advertisement

Finding the Sweet Spot: Balancing Reducing Ischemic Risk and Reducing Bleeding Risk with Antiplatelet Therapy

When to Shorten DAPT: Key Messages

Antiplatelet Therapy for Patients with Diabetes Undergoing PCI

Introduction

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

OCT Guidance Cuts Stent Use in STEMI Without Plaque Rupture: EROSION III

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

FAVOR III China Adds Strength to Value of QFR-Guided PCI

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Half-Dose DOAC May Be a Good Post-Watchman Option

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

LAA Closure Feasible in Patients With Thrombus: Registry

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Women Stand to Gain the Most From Standardized STEMI Protocols

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Long-term Anticoagulation After Unprovoked VTE: New Insights

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content